Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms [68Ga]Ga-PentixaFor, Gallium (68Ga) boclatixafortide, PentixaFor + [3] |
Target |
Action antagonists |
Mechanism CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Marginal Zone B-Cell Lymphoma | Phase 3 | Austria | 20 May 2024 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | France | 20 May 2024 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | Germany | 20 May 2024 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | Italy | 20 May 2024 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | Spain | 20 May 2024 | |
Hyperaldosteronism | Phase 3 | - | - | |
Primary Central Nervous System Lymphoma | Phase 2 | Denmark | 05 Oct 2022 | |
Primary Central Nervous System Lymphoma | Phase 2 | France | 05 Oct 2022 | |
Secondary Central Nervous System Lymphoma | Phase 2 | Denmark | 05 Oct 2022 | |
Secondary Central Nervous System Lymphoma | Phase 2 | France | 05 Oct 2022 |
Not Applicable | Multiple Myeloma First line | 25 | (Patients with decline in SUVmax of bone marrow < 40%) | vlmropzqmw(idozndyqdl) = iacvftwmbf oayaoovywh (hrodvkfjcf, 20.8 - 42.8) View more | - | 20 Jun 2025 | |
(Patients with visually reduced splenic uptake in follow-up PET/CT) | vlmropzqmw(idozndyqdl) = podtwaycll oayaoovywh (hrodvkfjcf, 18.5 - 31.9) View more | ||||||
Phase 1 | 19 | (AVS) | tytuzkkrxf(kzcinxdofn) = rpuxndhiyu msyoubzild (yqnklnrhxo ) | - | 01 Jun 2023 | ||
Not Applicable | - | (68Ga-Pentixafor PET/CT) | cvuyocoqrc(blxgciafzt) = ttqahgldcs iafsxnohzf (emdwjwzgqd, 12.1 - 16.4) | - | 08 Aug 2022 | ||
Early Phase 1 | - | (<sup>18</sup>F-FDG PET/CT) | gcwvmctokj(gdrwngdqiv) = wzkbyquabf edsaqxgnag (wdmgdxyslp ) | - | 01 Mar 2020 |